[{"id":"e381b221-6768-4bcf-80c5-d9caedaede97","acronym":"","url":"https://clinicaltrials.gov/study/NCT05898399","created_at":"2023-06-12T16:09:01.959Z","updated_at":"2024-07-02T16:35:01.189Z","phase":"Phase 1/2","brief_title":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients","source_id_and_acronym":"NCT05898399","lead_sponsor":"Artios Pharma Ltd","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • ART6043"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 05/14/2026","primary_completion_date":" 05/14/2026","study_txt":" Completion: 12/14/2026","study_completion_date":" 12/14/2026","last_update_posted":"2024-05-24"}]